quinacrine has been researched along with Neuroblastoma in 15 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
Excerpt | Relevance | Reference |
---|---|---|
"A clone of murine neuroblastoma (N1E-115) was shown to have functional receptors for the nonapeptide bradykinin." | 7.67 | Bradykinin receptor-mediated cyclic GMP formation in a nerve cell population (murine neuroblastoma clone N1E-115). ( Richelson, E; Snider, RM, 1984) |
"We previously reported that quinacrine inhibited the formation of an abnormal prion protein (PrPres), a key molecule in the pathogenesis of transmissible spongiform encephalopathy, or prion disease, in scrapie-infected neuroblastoma cells." | 3.72 | Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. ( Doh-Ura, K; Ishikawa, K; Iwaki, T; Kawatake, S; Kira, J; Murakami-Kubo, I; Ohta, S; Sasaki, K, 2004) |
"The activation of protein kinase C was investigated in digitonin-permeabilized human neuroblastoma SH-SY5Y cells by measuring the phosphorylation of the specific protein kinase C substrate myelin basic protein4-14." | 3.68 | Activation of protein kinase C in permeabilized human neuroblastoma SH-SY5Y cells. ( Larsson, C; Mau, S; Saermark, T; Simonsson, P, 1992) |
"Quinacrine altered the equilibrium binding of the muscarinic antagonist quinuclidinyl benzilate (QNB) to the muscarinic receptor in membranes from N18TG2 neuroblastoma cells." | 3.68 | Muscarinic receptor binding is inhibited by quinacrine. ( Howlett, AC; O'Donnell, KA, 1991) |
"A clone of murine neuroblastoma (N1E-115) was shown to have functional receptors for the nonapeptide bradykinin." | 3.67 | Bradykinin receptor-mediated cyclic GMP formation in a nerve cell population (murine neuroblastoma clone N1E-115). ( Richelson, E; Snider, RM, 1984) |
"Treatment with quinacrine did not prolong the survival times of prion-inoculated, wild-type or MDR(0/0) mice compared to untreated mice." | 1.35 | Continuous quinacrine treatment results in the formation of drug-resistant prions. ( Ahn, M; DeArmond, SJ; Ghaemmaghami, S; Giles, K; Legname, G; Lessard, P; Prusiner, SB, 2009) |
"Indomethacin was without effect in modifying the response." | 1.27 | Activation of cyclic nucleotide formation in murine neuroblastoma N1E-115 cells by modified human thrombins. ( Fenton, JW; McKinney, M; Richelson, E; Snider, RM, 1984) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (26.67) | 18.7374 |
1990's | 4 (26.67) | 18.2507 |
2000's | 5 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
Authors | Studies |
---|---|
May, BC | 2 |
Witkop, J | 1 |
Sherrill, J | 1 |
Anderson, MO | 1 |
Madrid, PB | 1 |
Zorn, JA | 1 |
Prusiner, SB | 3 |
Cohen, FE | 2 |
Guy, RK | 1 |
Rank, L | 1 |
Puhl, AC | 1 |
Havener, TM | 1 |
Anderson, E | 1 |
Foil, DH | 1 |
Zorn, KM | 1 |
Monakhova, N | 1 |
Riabova, O | 1 |
Hickey, AJ | 1 |
Makarov, V | 1 |
Ekins, S | 1 |
Biggi, S | 1 |
Pancher, M | 1 |
Stincardini, C | 1 |
Luotti, S | 1 |
Massignan, T | 1 |
Dalle Vedove, A | 1 |
Astolfi, A | 1 |
Gatto, P | 1 |
Lolli, G | 1 |
Barreca, ML | 1 |
Bonetto, V | 1 |
Adami, V | 1 |
Biasini, E | 1 |
Ghaemmaghami, S | 1 |
Ahn, M | 1 |
Lessard, P | 1 |
Giles, K | 1 |
Legname, G | 1 |
DeArmond, SJ | 1 |
Murakami-Kubo, I | 1 |
Doh-Ura, K | 2 |
Ishikawa, K | 1 |
Kawatake, S | 1 |
Sasaki, K | 1 |
Kira, J | 1 |
Ohta, S | 1 |
Iwaki, T | 2 |
Snider, RM | 2 |
McKinney, M | 1 |
Fenton, JW | 1 |
Richelson, E | 2 |
Murato, K | 1 |
Monard, D | 1 |
Lee, RK | 1 |
Wurtman, RJ | 1 |
Cox, AJ | 1 |
Nitsch, RM | 1 |
Ray, R | 1 |
Legere, RH | 1 |
Majerus, BJ | 1 |
Petrali, JP | 1 |
Caughey, B | 1 |
Korth, C | 1 |
Larsson, C | 1 |
Saermark, T | 1 |
Mau, S | 1 |
Simonsson, P | 1 |
O'Donnell, KA | 1 |
Howlett, AC | 1 |
Inoue, S | 1 |
Ravindranath, Y | 1 |
Ottenbreit, MJ | 1 |
Thompson, RI | 1 |
Zuelzer, WW | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease[NCT00183092] | Phase 2 | 69 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter D) is phonemic. Higher scores indicate better cognition." (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | number of words generated (Mean) |
---|---|
Placebo | -2.4 |
Quinacrine | -2.2 |
ADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 13.0 |
Quinacrine | 12.6 |
An ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone. (NCT00183092)
Timeframe: baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | -23.2 |
Quinacrine | -13.2 |
Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 3.2 |
Quinacrine | 0.3 |
The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing. (NCT00183092)
Timeframe: Baseline to Month-2
Intervention | units on a scale (Mean) |
---|---|
Placebo | -6.9 |
Quinacrine | -3.9 |
"The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone." (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 0.8 |
Quinacrine | 0.3 |
Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | number of words generated (Mean) |
---|---|
Placebo | -3.2 |
Quinacrine | -2.2 |
Participants alive after 2 months on study treatment (NCT00183092)
Timeframe: Randomization to Month-2
Intervention | participants (Number) |
---|---|
Placebo | 19 |
Quinacrine | 13 |
15 other studies available for quinacrine and Neuroblastoma
Article | Year |
---|---|
Structure-activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cells.
Topics: Aminacrine; Cell Line; Cell Survival; Humans; Molecular Structure; Neuroblastoma; Scrapie; Structure | 2006 |
Multiple approaches to repurposing drugs for neuroblastoma.
Topics: Bayes Theorem; Cell Line, Tumor; Child; Child, Preschool; Crizotinib; Drug Repositioning; Etoposide; | 2022 |
Identification of compounds inhibiting prion replication and toxicity by removing PrP
Topics: Animals; Casein Kinase II; Cell Line, Tumor; Cell Membrane; Cell Survival; Drug Evaluation, Preclini | 2020 |
Continuous quinacrine treatment results in the formation of drug-resistant prions.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; | 2009 |
Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies.
Topics: Animals; Brain; Humans; Immunohistochemistry; Injections, Intraventricular; Mice; Mice, Transgenic; | 2004 |
Activation of cyclic nucleotide formation in murine neuroblastoma N1E-115 cells by modified human thrombins.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Antioxidants; Catechols; Cell Line; Cyclic GMP; Humans; In | 1984 |
Bradykinin receptor-mediated cyclic GMP formation in a nerve cell population (murine neuroblastoma clone N1E-115).
Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Bradykinin; Calcium; Catechols; Cell Line; Clone Cells; Cy | 1984 |
Inhibition of S-adenosylmethionine-linked methylation can lead to neurite extension in neuroblastoma cells.
Topics: Animals; Calcimycin; Clone Cells; Methylation; Mice; Neoplasms, Experimental; Neuroblastoma; Neurons | 1982 |
Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors.
Topics: Alanine; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Line; Chelating Agents | 1995 |
Sulfur mustard-induced increase in intracellular free calcium level and arachidonic acid release from cell membrane.
Topics: Animals; Arachidonic Acid; Calcium; Cell Membrane; Cell Survival; Glioma; Glutathione; Hybrid Cells; | 1995 |
Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation.
Topics: Animals; Cysteine Proteinase Inhibitors; Inhibitory Concentration 50; Leucine; Lysosomes; Neuroblast | 2000 |
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
Topics: Acridines; Animals; Cells, Cultured; Chlorpromazine; Fatty Acids; Humans; Mice; Neuroblastoma; Pheno | 2001 |
Activation of protein kinase C in permeabilized human neuroblastoma SH-SY5Y cells.
Topics: Acetophenones; Amino Acid Sequence; Arachidonic Acids; Calcium; Cell Membrane; Cell Membrane Permeab | 1992 |
Muscarinic receptor binding is inhibited by quinacrine.
Topics: Binding, Competitive; Calcium; Carbachol; Cyclic AMP; Muscarinic Antagonists; Neuroblastoma; Quinacr | 1991 |
Chromosomal analysis of metastatic retinoblastoma cells.
Topics: Bone Marrow Cells; Cerebrospinal Fluid; Child, Preschool; Chromosome Aberrations; Humans; Karyotypin | 1974 |